U.S. markets closed

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.63-0.37 (-1.85%)
At close: 4:00PM EDT
Sign in to post a message.
  • M
    Matthew
    NBIX has a stake in the success in XENE. Sold half my NBIX and bought XENE; I’m up 50%...so far:)
  • M
    Matthew
    Decent report and Conference Call by XENE management. NBIX needs them more then ever; after reporting big fail on schizophrenia drug this morning.
  • H
    Health Master
    (XENE) Cup and handle, Rounded bottom, positive indicator.
  • H
    Health Master
    Xenon Pharmaceuticals Announces Promising New Pre-Clinical Data and Provides Clinical Overview of its XEN1101 Program at ASENT 2021.
  • H
    Health Master
    Looking at (XENE) Comparable Liquid Assets multiple of 6-10x Cash & Short Term Investments, valuation of $25-30.
    Bullish
  • H
    Health Master
    Xene has $200MM Liquid Assets, with a Mkt Cap. of $500MM (only 2.5x Liquidity), GWPH had cash of $500MM, and Mkt. Cap of 3BB (6x liquidity), before being bought out for 6BB (over 10x liquidity). At 6-10x Liquid Assets, Xene would be at the high range of the price target $25-30 per share.
    Bullish
  • Y
    Yahoo Finance Insights
    Xenon Pharmaceuticals is up 9.60% to 21.35
  • H
    Health Master
    Low price Target of 22, High of 25 by Needham, Wedbush, & William Blair.
    Bullish
  • H
    Health Master
    Small float: 20MM, so buy as much as you can at this price.
    Bullish
  • H
    Harley Dog
    I recently saw a buy rating initiated with an amazing $25 price target, but still losing tons of money. Not much news to come by. What gives?
  • a
    anonymous
    News out soon. Great setup technically.
  • M
    Mick 69
    Where can I find the best reliable info about this company? I never heard of it before but it looks good! thanks
  • S
    Stanley
    The Teva termination news is two weeks old... On March 7, 2018, Teva Pharmaceutical (TEVA) with Teva Canada and Xenon Pharmaceuticals (XENE) entered into a mutual agreement to terminate the collaborative development and license agreement they entered into in 2012 for the pain drug TV-45070. During Xenon Pharmaceuticals’ 2017 earnings results release, it announced the agreement termination news. On the day, TEVA stock rose ~0.8%, while Xenon stock rose ~7%. Teva Pharmaceutical stated that it was no longer interested in the development of TV-45070.
  • D
    Deacon
    If they can master treatment for epilepsy , which they have 2 trials a phase 1 will be huge for xene. Financially in good shape for 2018.
  • D
    Deacon
    Up 22 cents in down market,nice move know have a profit . Please don’t delete.
  • D
    Deacon
    Any pr news out there.? A little positive guidance would be helpful.
  • D
    Deacon
    One would think Genentech wouldd make a run at them before stock gets to high. Just holding on for awhile we.
  • m
    max
    I bought it shortly after it went IPO at 12, sold at about 22 or so on the speculation bubble, many insiders sold at highs Have been watching it tank. It has been oversold at this point. Insiders have bought the stock back in the past few months. Some good possibilities in the pipeline, and the company is not a new one (over 20 years old). It will likely go to $6-$8 in the next 12-18 months, provided even one of its trials pans out. I just re-bought a small amount and will buy more when I can
  • T
    Trillion
    to the sky we go..
  • D
    Deacon
    Finally the market is recognizing the huge potential in the treatment of epilepsy, are now in 2 phase II trials.